Security
Adlai Nortye Group Ltd. American Depositary Shares · ANL
ANLNASDAQotherCurrentCIK 1944552Updated Oct 29, 2026
ANL price & chart
Loading TradingView…
NASDAQ:ANL on TradingView ↗About the company
Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas: 1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company’s proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Profit or LossUSD | -51,869,000Source | -104,871,000Source | -58,790,000Source |
| Additional Financial Items | |||
| AdjustmentsForFinanceCostsUSD | 1,944,000Source | 791,000Source | 433,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -4,202,000Source | 1,252,000Source | 10,117,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 2,450,000Source | 4,330,000Source | 6,082,000Source |
| GeneralAndAdministrativeExpenseUSD | 9,953,000Source | — | — |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 1,871,000Source | 602,000Source | 292,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 1,020,000Source | 1,103,000Source | 1,070,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 44,702,000Source | 50,234,000Source | 7,897,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | 33,000Source | 1,000Source | 17,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | 19,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 48,542,000Source | 24,069,000Source | 13,315,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Additional Financial Items | |||
| AdministrativeExpenseUSD | 9,953,000Source | 15,289,000Source | 13,039,000Source |
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source |
| BasicEarningsLossPerShareUSD per share | -0.54Source | -2.42Source | -2.31Source |
| CurrentTaxExpenseIncomeUSD | — | 643,000Source | — |
| DepreciationAndAmortisationExpenseUSD | 510,000Source | — | — |
| DepreciationRightofuseAssetsUSD | 866,000Source | 984,000Source | 1,090,000Source |
| DilutedEarningsLossPerShareUSD per share | -0.54Source | -2.42Source | -2.31Source |
| EmployeeBenefitsExpenseUSD | 5,994,000Source | — | — |
| FinanceCostsUSD | 1,944,000Source | 791,000Source | 433,000Source |
| GeneralAndAdministrativeExpenseUSD | 9,953,000Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | 643,000Source | — |
| InterestExpenseOnLeaseLiabilitiesUSD | 50,000Source | 83,000Source | 133,000Source |
| OtherEmployeeExpenseUSD | 437,000Source | — | — |
| OtherOperatingIncomeExpenseUSD | 1,940,000Source | 890,000Source | 259,000Source |
| ProfessionalFeesExpenseUSD | 1,735,000Source | — | — |
| ProfitLossAttributableToOwnersOfParentUSD | -51,869,000Source | -104,871,000Source | -58,790,000Source |
| ProfitLossBeforeTaxUSD | -51,869,000Source | -104,228,000Source | -58,790,000Source |
| ProfitLossFromOperatingActivitiesUSD | -52,928,000Source | -67,551,000Source | -67,270,000Source |
| ResearchAndDevelopmentExpenseUSD | 44,915,000Source | 58,152,000Source | 54,490,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | -4,000Source | — | — |
Offerings
Registration 333-294173
Filing attachments
ea030991901ex99-1.htm · 6-K · 2026-10-28
Exhibit 99.1 Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38 th EORTC-NCI-AACR Symposium AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4035 AN4035 is a novel CEACAM5-targeting ADC armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window 2026-10-27 SINGAPORE and…
Read attachment ↗ea030870701ex99-1.htm · 6-K · 2026-10-15
Exhibit 99.1 Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial Cetuximab will be supplied by Lilly for the U.S. trial sites Cetuximab will be supplied by Merck KGaA, Darmstadt, Germany for the Australia and China trial sites 2…
Read attachment ↗ea030697801ex99-1.htm · 6-K · 2026-09-30
Exhibit 99.1 Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) - Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of…
Read attachment ↗ea030481202ex4-6.htm · POS AM · 2026-09-11
Exhibit 4.6 Adlai Nortye Group Ltd., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗ea030480101ex99-1.htm · 6-K · 2026-09-08
Exhibit 99.1 Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor - designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with “Study-May-Proceed” letter SINGAPORE and NORTH BRUNSWICK, N.J., September 8 th, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd…
Read attachment ↗ea030291401ex99-1.htm · 6-K · 2026-08-26
Exhibit 99.1 ADLAI NORTYE GROUP LTD. 77 Robinson Road #20-01 Robinson 77 Singapore 068896 NOTICE OF 2026 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERSTo Be Held on September 30, 2026 at 10 a.m., Singapore time To the Shareholders of Adlai Nortye Group Ltd.: This notice to shareholders is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board”) of Adlai Nortye Group Ltd. (the “Company”) at the 2026 Extraordinary General Meeting of shareholders of the Co…
Read attachment ↗